Rejuveron Life Sciences AG, a leader in biotechnology focusing on aging therapies, successfully secured a USD $75 million Series B funding, co-led by Catalio Capital Management and Apeiron Investment Group. This financing will fuel the expansion of their innovative medicine portfolio, aiming to enhance longevity and quality of life.
Expanding its global footprint, Rejuveron has announced the opening of a new office in Abu Dhabi, UAE, aligning with the Middle East’s healthcare innovation strategy. This strategic move is set to transform the UAE into a hub for longevity research, with collaborations with local institutions like NYU Abu Dhabi.
Adding to its pioneering efforts, Rejuveron has invested in Boost Neuroscience, spearheaded by Nobel laureate Dr. Thomas Sudhof, focusing on brain synapse regeneration. This acquisition is part of Rejuveron’s commitment to advancing aging science and developing therapies that address unmet needs in brain health.
The company’s robust approach in tackling aging diseases, supported by international investors including the new addition of Mubadala Capital, positions Rejuveron as a global frontrunner in longevity science. With strategic bases in Switzerland and the UAE, Rejuveron continues to push the boundaries of biotechnological innovation in aging.